CHAD Therapeutics Financial Statements
CHAD Therapeutics Financial Information
| Company Type | Public Single Location |
|---|---|
| Fiscal Year-End | March |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
CHAD Therapeutics Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 19.0 | 22.4 |
| Gross Profit ($ mil.) | -- | 5.3 | 7.2 |
| Operating Income ($ mil.) | (3.1) | (2.5) | (1.1) |
| Total Net Income ($ mil.) | (8.6) | (3.4) | (0.7) |
| Diluted EPS (Net Income) | 0.85 | (0.34) | (0.07) |
CHAD Therapeutics Quarterly Statements
| Quarter Ending Jun 08* | Quarter Ending Dec 07 | Quarter Ending Sep 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 2.9 | 3.2 |
| Gross Profit ($ mil.) | -- | 1.2 | 0.6 |
| Operating Income ($ mil.) | (0.6) | (0.7) | (1.2) |
| Total Net Income ($ mil.) | (0.6) | (0.9) | (1.4) |
| Diluted EPS (Net Income) | (0.06) | 0.60 | (0.13) |
- * Irregular reporting interval
CHAD Therapeutics Stock Quote & Chart
•
•
--
•
•
%
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
CHAD Therapeutics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | -- | 2.02 | 1.48 |
| Price/Earnings Ratio | 0.18 | 21.52 | 15.35 |
| Price/Book Ratio | 1.30 | 2.03 | 1.44 |
| Price/Cash Flow Ratio | -- | 15.52 | 9.34 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed CHAD Therapeutics Financial Ratios
CHAD Therapeutics Competitive Intelligence
| Covidien | ResMed | Respironics | |
|---|---|---|---|
| Annual Sales ($ mil.) | 10,170.0 | 835.4 | 1,195.0 |
| Employees | 43,800 | -- | 4,900 |
| Market Cap ($ mil.) | 28,173.9 | 3,435.6 | -- |
Competitive Landscape
